Second Department of Surgery, Dokkyo Medical University, Mibu, Japan.
Chemotherapy. 2010;56(6):501-6. doi: 10.1159/000321014. Epub 2010 Nov 24.
We analyzed the outcome of patients with advanced unresectable pancreatic cancer treated in our department from 2001 to 2008.
Of the 83 patients included in this study, 50 patients received single-agent treatment with gemcitabine (GEM), 9 patients GEM combined with radiotherapy (GEM+R) and 24 patients had best supportive care (BSC). We analyzed survival rates among the groups and risk factors for each group.
The 3-year survival rates were dismal: GEM group 2.9%, GEM+R group 0% and BSC group 0%. Significant prognostic factors of the study were: performance status (PS), response rate and decrease in the CA19-9 level. Significant prognostic factors by the Cox proportional hazard model were the albumin level prior to treatment, CA19-9 levels before treatment, decrease in CA19-9 and response rate. Albumin levels and the Glasgow Prognostic Score (GPS) were found to be factors affecting survival in the GEM group.
In this series of patients with unresectable pancreatic cancer, good PS, decrease in CA19-9 after treatment and good GPS determined prior to treatment were independent prognostic factors for better overall survival.
我们分析了 2001 年至 2008 年在我科治疗的晚期不可切除胰腺癌患者的预后。
本研究共纳入 83 例患者，其中 50 例接受单药吉西他滨（GEM）治疗，9 例接受 GEM 联合放疗（GEM+R），24 例接受最佳支持治疗（BSC）。我们分析了各组的生存率和各组的危险因素。
3 年生存率很低：GEM 组为 2.9%，GEM+R 组为 0%，BSC 组为 0%。该研究的显著预后因素为：体能状态（PS）、缓解率和 CA19-9 水平降低。Cox 比例风险模型的显著预后因素为治疗前白蛋白水平、治疗前 CA19-9 水平、CA19-9 降低和缓解率。白蛋白水平和格拉斯哥预后评分（GPS）被发现是 GEM 组生存的影响因素。
在这一系列不可切除的胰腺癌患者中，良好的 PS、治疗后 CA19-9 降低和治疗前良好的 GPS 是总体生存的独立预后因素。
